Log in

NASDAQ:AQSTAquestive Therapeutics News Headlines

$4.71
-0.03 (-0.63 %)
(As of 07/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$4.54
Now: $4.71
$4.82
50-Day Range
$4.74
MA: $5.31
$6.44
52-Week Range
$1.41
Now: $4.71
$10.00
Volume734,572 shs
Average Volume869,013 shs
Market Capitalization$158.18 million
P/E RatioN/A
Dividend YieldN/A
Beta3.6

Headlines

Aquestive Therapeutics (NASDAQ AQST) News Headlines

Source:
DateHeadline
Aquestive Therapeutics (NASDAQ:AQST) Earns "Buy" Rating from WedbushAquestive Therapeutics (NASDAQ:AQST) Earns "Buy" Rating from Wedbush
www.americanbankingnews.com - July 1 at 6:57 AM
Aquestive Therapeutics (NASDAQ:AQST) Earns Buy Rating from HC WainwrightAquestive Therapeutics (NASDAQ:AQST) Earns Buy Rating from HC Wainwright
www.americanbankingnews.com - July 1 at 6:57 AM
BRIEF-Aquestive Files IND For Pharmacokinetic Clinical Trials Of Aqst-108 For Anaphylaxis TreatmentBRIEF-Aquestive Files IND For Pharmacokinetic Clinical Trials Of Aqst-108 For Anaphylaxis Treatment
www.reuters.com - June 29 at 5:37 PM
Aquestive files IND for pharmacokinetic trials of AQST-108Aquestive files IND for pharmacokinetic trials of AQST-108
seekingalpha.com - June 29 at 12:36 PM
Aquestive to advance AQST-108 into the clinicAquestive to advance AQST-108 into the clinic
seekingalpha.com - June 29 at 12:36 PM
Aquestive Therapeutics Files IND for Pharmacokinetic Clinical Trials of AQST-108 (Sublingual Film Formulation Delivering Systemic Epinephrine) for Anaphylaxis TreatmentAquestive Therapeutics Files IND for Pharmacokinetic Clinical Trials of AQST-108 (Sublingual Film Formulation Delivering Systemic Epinephrine) for Anaphylaxis Treatment
finance.yahoo.com - June 29 at 7:31 AM
$9.14 Million in Sales Expected for Aquestive Therapeutics Inc (NASDAQ:AQST) This Quarter$9.14 Million in Sales Expected for Aquestive Therapeutics Inc (NASDAQ:AQST) This Quarter
www.americanbankingnews.com - June 29 at 2:48 AM
Aquestive Therapeutics Inc (NASDAQ:AQST) Expected to Post Earnings of -$0.43 Per ShareAquestive Therapeutics Inc (NASDAQ:AQST) Expected to Post Earnings of -$0.43 Per Share
www.americanbankingnews.com - June 27 at 11:31 AM
Aquestive Therapeutics Inc (NASDAQ:AQST) Receives Consensus Recommendation of "Buy" from AnalystsAquestive Therapeutics Inc (NASDAQ:AQST) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - June 11 at 1:30 AM
Aquestive Therapeutics to Hold Virtual-Only Annual Meeting of StockholdersAquestive Therapeutics to Hold Virtual-Only Annual Meeting of Stockholders
finance.yahoo.com - June 4 at 5:30 PM
Implied Volatility Surging for Aquestive Therapeutics (AQST) Stock OptionsImplied Volatility Surging for Aquestive Therapeutics (AQST) Stock Options
finance.yahoo.com - May 28 at 2:49 PM
Why Aquestive Therapeutics (AQST) Stock Might be a Great PickWhy Aquestive Therapeutics (AQST) Stock Might be a Great Pick
finance.yahoo.com - May 27 at 1:02 PM
Aquestive Therapeutics Advances Royalty Monetization Plan as Sunovion Pharmaceuticals Apomorphine Sublingual Film Therapy Receives FDA ApprovalAquestive Therapeutics Advances Royalty Monetization Plan as Sunovion Pharmaceuticals' Apomorphine Sublingual Film Therapy Receives FDA Approval
www.benzinga.com - May 23 at 11:34 PM
Aquestive Therapeutics Advances Royalty Monetization Plan as Sunovion Pharmaceuticals’ Apomorphine Sublingual Film Therapy Receives FDA ApprovalAquestive Therapeutics Advances Royalty Monetization Plan as Sunovion Pharmaceuticals’ Apomorphine Sublingual Film Therapy Receives FDA Approval
finance.yahoo.com - May 21 at 6:42 PM
Is Aquestive Therapeutics (AQST) Outperforming Other Medical Stocks This Year?Is Aquestive Therapeutics (AQST) Outperforming Other Medical Stocks This Year?
finance.yahoo.com - May 20 at 2:53 PM
Aquestive Therapeutics Shares March Higher, Can It Continue?Aquestive Therapeutics' Shares March Higher, Can It Continue?
www.nasdaq.com - May 14 at 10:12 AM
Aquestive Therapeutics' Shares March Higher, Can It Continue?Aquestive Therapeutics' Shares March Higher, Can It Continue?
finance.yahoo.com - May 14 at 10:12 AM
Aquestive Therapeutics to Present at 2020 RBC Capital Markets Global Healthcare ConferenceAquestive Therapeutics to Present at 2020 RBC Capital Markets Global Healthcare Conference
finance.yahoo.com - May 7 at 3:21 PM
Aquestive Therapeutics Reports First Quarter 2020 Financial Results and Provides Business Update: AQST-108 and Libervant Remain On TrackAquestive Therapeutics Reports First Quarter 2020 Financial Results and Provides Business Update: AQST-108 and Libervant Remain On Track
finance.yahoo.com - May 5 at 8:58 PM
Aquestive: Still Looking To Buy In 2020Aquestive: Still Looking To Buy In 2020
seekingalpha.com - April 27 at 10:11 AM
3 Biotech Stocks Under $4 With Big Upside Potential3 Biotech Stocks Under $4 With Big Upside Potential
finance.yahoo.com - April 26 at 8:00 AM
Aquestive Therapeutics to Announce First Quarter Financial Results and Recent Business Highlights on May 5 and Host Investment Community Conference Call on May 6Aquestive Therapeutics to Announce First Quarter Financial Results and Recent Business Highlights on May 5 and Host Investment Community Conference Call on May 6
finance.yahoo.com - April 21 at 2:10 PM
Aquestive Therapeutics (AQST): Strong Industry, Solid Earnings Estimate RevisionsAquestive Therapeutics (AQST): Strong Industry, Solid Earnings Estimate Revisions
finance.yahoo.com - April 15 at 12:31 PM
Aquestive Therapeutics, Inc. Just Reported Full-Year Earnings: Have Analysts Changed Their Mind On The Stock?Aquestive Therapeutics, Inc. Just Reported Full-Year Earnings: Have Analysts Changed Their Mind On The Stock?
finance.yahoo.com - March 14 at 8:37 AM
Company News for Mar 13, 2020Company News for Mar 13, 2020
finance.yahoo.com - March 13 at 12:36 PM
Aquestive Therapeutics (AQST) Reports Q4 Loss, Tops Revenue EstimatesAquestive Therapeutics (AQST) Reports Q4 Loss, Tops Revenue Estimates
finance.yahoo.com - March 12 at 12:01 AM
Aquestive Therapeutics EPS misses by $0.10, beats on revenueAquestive Therapeutics EPS misses by $0.10, beats on revenue
seekingalpha.com - March 11 at 7:00 PM
Aquestive Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Business HighlightsAquestive Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Business Highlights
finance.yahoo.com - March 11 at 7:00 PM
The Global Epilepsy Market, Pipeline and Competition 2020-2030 - Aquestive Therapeuticals AQST-203 Will Be a Blockbuster DrugThe Global Epilepsy Market, Pipeline and Competition 2020-2030 - Aquestive Therapeutical's AQST-203 Will Be a Blockbuster Drug
www.prnewswire.com - March 9 at 4:55 PM
Aquestive Therapeutics to Announce Fourth Quarter and Full Year 2019 Financial Results and Recent Business Highlights on March 12, 2020Aquestive Therapeutics to Announce Fourth Quarter and Full Year 2019 Financial Results and Recent Business Highlights on March 12, 2020
finance.yahoo.com - February 20 at 7:37 AM
Aquestive Therapeutics, Inc. Common Stock (AQST) Dividend HistoryAquestive Therapeutics, Inc. Common Stock (AQST) Dividend History
www.nasdaq.com - February 12 at 5:19 PM
ACST Plunges On Data Delay, MREO On Watch, AQST Faces FDA In Sep.ACST Plunges On Data Delay, MREO On Watch, AQST Faces FDA In Sep.
www.nasdaq.com - February 11 at 12:09 AM
FDA accepts Aquestives Libervant NDA; shares up 6% premarketFDA accepts Aquestive's Libervant NDA; shares up 6% premarket
seekingalpha.com - February 10 at 9:04 AM
Aquestive Therapeutics Announces U.S. Food and Drug Administration Filing Acceptance of New Drug Application (NDA) for Libervant™ (diazepam) Buccal FilmAquestive Therapeutics Announces U.S. Food and Drug Administration Filing Acceptance of New Drug Application (NDA) for Libervant™ (diazepam) Buccal Film
finance.yahoo.com - February 10 at 9:04 AM
Aquestive Therapeutics, Inc. Common Stock (AQST) Institutional Holdings | NasdaqAquestive Therapeutics, Inc. Common Stock (AQST) Institutional Holdings | Nasdaq
www.nasdaq.com - February 6 at 11:29 PM
5 Biotechnology Stocks Moving In Thursdays Pre-Market Session5 Biotechnology Stocks Moving In Thursday's Pre-Market Session
www.benzinga.com - February 6 at 1:28 PM
Why This First of Its Kind Anaphylaxis Treatment Could Be HugeWhy This First of Its Kind Anaphylaxis Treatment Could Be Huge
247wallst.com - February 6 at 1:28 PM
Aquestive up 9% premarket on abbreviated pathway for AQST-108Aquestive up 9% premarket on abbreviated pathway for AQST-108
seekingalpha.com - February 6 at 8:27 AM
Aquestive Therapeutics Announces FDA Confirmed...Aquestive Therapeutics Announces FDA Confirmed...
www.benzinga.com - February 6 at 8:27 AM
Aquestive Therapeutics Announces FDA Confirmed 505(b)(2) Pathway for AQST-108 (Sublingual Film Formulation Delivering Systemic Epinephrine) for Anaphylaxis TreatmentAquestive Therapeutics Announces FDA Confirmed 505(b)(2) Pathway for AQST-108 (Sublingual Film Formulation Delivering Systemic Epinephrine) for Anaphylaxis Treatment
finance.yahoo.com - February 6 at 8:27 AM
Aquestive Therapeutics, Inc. Common Stock (AQST) Revenue EPSAquestive Therapeutics, Inc. Common Stock (AQST) Revenue EPS
www.nasdaq.com - January 30 at 11:36 PM
Why Aquestive Therapeutics’ Seizure Treatment May Get Butted OutWhy Aquestive Therapeutics’ Seizure Treatment May Get Butted Out
247wallst.com - January 13 at 5:40 PM
Aquestive avoids potential roadblock to U.S. approval of LibervantAquestive avoids potential roadblock to U.S. approval of Libervant
seekingalpha.com - January 12 at 10:40 PM
Aquestive Therapeutics Receives FDA Response to Citizen’s PetitionAquestive Therapeutics Receives FDA Response to Citizen’s Petition
finance.yahoo.com - January 12 at 10:40 PM
Aquestive sees Q4 revenue above consensus; shares ahead 13% premarketAquestive sees Q4 revenue above consensus; shares ahead 13% premarket
seekingalpha.com - January 10 at 8:51 AM
Aquestive Therapeutics Exceeds Top End of...Aquestive Therapeutics Exceeds Top End of...
www.benzinga.com - January 10 at 8:51 AM
Aquestive Therapeutics Exceeds Top End of Guidance Range for Preliminary Unaudited Full Year 2019 Total Revenues and Provides Initial Full Year 2020 GuidanceAquestive Therapeutics Exceeds Top End of Guidance Range for Preliminary Unaudited Full Year 2019 Total Revenues and Provides Initial Full Year 2020 Guidance
finance.yahoo.com - January 10 at 8:51 AM
Aquestive: Continues To Evolve Into A Promising Long-Term InvestmentAquestive: Continues To Evolve Into A Promising Long-Term Investment
seekingalpha.com - January 6 at 3:54 PM
Did Hedge Funds Drop The Ball On Aquestive Therapeutics, Inc. (AQST) ?Did Hedge Funds Drop The Ball On Aquestive Therapeutics, Inc. (AQST) ?
finance.yahoo.com - December 22 at 8:28 PM
Did Changing Sentiment Drive Aquestive Therapeuticss (NASDAQ:AQST) Share Price Down By 22%?Did Changing Sentiment Drive Aquestive Therapeutics's (NASDAQ:AQST) Share Price Down By 22%?
finance.yahoo.com - December 17 at 9:28 AM
This page was last updated on 7/3/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.